Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Tuesday. The firm issued a sell rating on the stock.

Bio-Path Stock Down 2.0 %

Bio-Path stock opened at $0.70 on Tuesday. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.36. Bio-Path has a twelve month low of $0.59 and a twelve month high of $12.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities & Exchange Commission. 5.74% of the stock is currently owned by institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.